A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: A comparative study with human parathyroid hormone

被引:28
作者
Khan, M. P. [1 ,5 ,6 ]
Mishra, J. S. [2 ,5 ,6 ]
Sharan, K. [1 ,5 ,6 ]
Yadav, M. [2 ,5 ,6 ]
Singh, A. K. [2 ,5 ,6 ]
Srivastava, A. [3 ,6 ]
Kumar, S. [4 ,5 ,6 ]
Bhaduaria, S. [3 ,6 ]
Maurya, R. [4 ,5 ,6 ]
Sanyal, S. [2 ,5 ,6 ]
Chattopadhyay, N. [1 ,5 ,6 ]
机构
[1] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226021, Uttar Pradesh, India
[2] CSIR Cent Drug Res Inst, Div Drug Target Discovery & Dev, Lucknow 226021, Uttar Pradesh, India
[3] CSIR Cent Drug Res Inst, Div Toxicol, Lucknow 226021, Uttar Pradesh, India
[4] CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226021, Uttar Pradesh, India
[5] CSIR Cent Drug Res Inst, Ctr Res Anabol Skeletal Targets Hlth & Illness AS, Lucknow 226021, Uttar Pradesh, India
[6] CSIR Cent Drug Res Inst, CDDDRH, Lucknow 226021, Uttar Pradesh, India
关键词
Glucocorticoid-induced osteoporosis; Bone histomorphometry; Bone anabolic; AKT pathway; Runx-2; Quercetin; CORTICOSTEROID-INDUCED OSTEOPOROSIS; INTERMITTENT TREATMENT; OSTEOPROGENITOR CELLS; DIFFERENTIATION; APOPTOSIS; RATS; INHIBITION; MECHANISMS; RECEPTOR; STIMULATION;
D O I
10.1016/j.phymed.2013.07.007
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Purpose: 6-C-beta-D-glucopyranosyl-(2S,3S)-(+)-5,7,3',4'-tetrahydroxydihydroflavonol (GTDF) is a novel compound isolated from Ulmus wallichiana, reported to have bone anabolic action in ovariectomized rats. Here, we studied the effect of GTDF in glucocorticoid (GC)-induced bone loss and its mode of action. Methods: Osteoblasts were cultured from rat calvaria or bone marrow to study apoptosis and differentiation by dexamethasone (Dex), methylprednisolone (MP), GTDF, quercetin and rutin. Female Sprague Dawley rats were treated with Dex or MP with or without GTDF or PTH. Efficacy was evaluated by bone microarchitecture using microcomputed tomography, determination of new bone formation by fluorescent labeling of bone and osteoblast apoptosis by co-labeling bone sections with Runx-2 and TUNEL. Serum osteocalcin was determined by ELISA. Results: GTDF preserved trabecular and cortical bones in the presence of Dex and MP and mitigated the MP-mediated suppression of serum osteocalcin. Co-administration of GTDF to MP rats increased mineral apposition, bone formation rates, bone biomechanical strength, reduced osteoblast apoptosis and increased osteogenic differentiation of bone marrow stromal cells compared to MP group, suggesting in vivo osteogenic effect of GTDF. These effects of GTDF were to a great extent comparable to PTH. GTDF prevented GC-induced osteoblast apoptosis by inhibiting p53 expression and acetylation, and activation of AKT but did not influence transactivation of GC receptor (GR). Conclusions: GTDF protects against GC-induced bone loss by promoting osteoblast survival through p53 inhibition and activation of AKT pathways but not as a GR antagonist. GTDF has the potential in the management of GC-induced osteopenia. (C) 2013 Elsevier GmbH. All rights reserved.
引用
收藏
页码:1256 / 1266
页数:11
相关论文
共 46 条
[1]   Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT [J].
Almeida, M ;
Han, L ;
Bellido, T ;
Manolagas, SC ;
Kousteni, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (50) :41342-41351
[2]   Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts [J].
Almeida, Maria ;
Han, Li ;
Ambrogini, Elena ;
Weinstein, Robert S. ;
Manolagas, Stavros C. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (52) :44326-44335
[3]   The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: A meta-regression [J].
Amin, S ;
Lavalley, MP ;
Simms, RW ;
Felson, DT .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (08) :1512-1526
[4]   Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate [J].
Bitto, A. ;
Burnett, B. P. ;
Polito, F. ;
Levy, R. M. ;
Marini, H. ;
Di Stefano, V. ;
Irrera, N. ;
Armbruster, M. A. ;
Minutoli, L. ;
Altavilla, D. ;
Squadrito, F. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 156 (08) :1287-1295
[5]   Ultrastructural characteristics of glucocorticoid-induced osteoporosis [J].
Bouvard, B. ;
Audran, M. ;
Legrand, E. ;
Chappard, D. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (06) :1089-1092
[6]   Glucocorticoid-induced osteoporosis: pathophysiology and therapy [J].
Canalis, E. ;
Mazziotti, G. ;
Giustina, A. ;
Bilezikian, J. P. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (10) :1319-1328
[8]  
Carpinteri R, 2010, J Endocrinol Invest, V33, P16
[9]   Sirt1 Is a Regulator of Bone Mass and a Repressor of Sost Encoding for Sclerostin, a Bone Formation Inhibitor [J].
Cohen-Kfir, Einav ;
Artsi, Hanna ;
Levin, Avi ;
Abramowitz, Eva ;
Bajayo, Alon ;
Gurt, Irina ;
Zhong, Lei ;
D'Urso, Agustina ;
Toiber, Debra ;
Mostoslavsky, Raul ;
Dresner-Pollak, Rivka .
ENDOCRINOLOGY, 2011, 152 (12) :4514-4524
[10]   Quercetin prevents experimental glucocorticoid-induced osteoporosis: a comparative study with alendronate [J].
Derakhshanian, Hoda ;
Djalali, Mahmoud ;
Djazayery, Abolghassem ;
Nourijelyani, Keramat ;
Ghadbeigi, Sajad ;
Pishva, Hamideh ;
Saedisomeolia, Ahmad ;
Bahremand, Arash ;
Dehpour, Ahmad Reza .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2013, 91 (05) :380-385